Turkiye Klinikleri Journal of Medical Sciences

.: REVIEW
Experimental Models Used in Neurosurgery Practice and Selection of an Appropriate Model
Nöroşirurji Pratiğinde Kullanılan Deney Modelleri ve Uygun Model Seçimi
Nuray VAROL KAYAPUNARa, Hasan Emre AYDINb
aDepartment of Histology and Embryology, Bursa Uludağ University Faculty of Veterinary Medicine, Bursa, TURKEY
bDepartment of Aeronautical and Space Medicine, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, TURKEY
Turkiye Klinikleri J Med Sci. 2021;41(1):86-94
doi: 10.5336/medsci.2020-80465
Article Language: EN
Full Text
ABSTRACT
 The role of animal experiments in the progress of medicine and its current stage has a significant effect. Most of the research in the medical and veterinary fields requires the use of experimental animals. It is a possible fact that the next experimental studies will be realized with the contribution of animal experiments. On the other hand, since humans cannot be included in experimental studies due to ethical reasons, the use of animals is mandatory. There are many models in which experimental animals are used. However, the use of experimental animals also brings some disadvantages. Experimental animals cannot be used randomly for scientific or any other purpose. Even if the experimental protocol was carried out properly, it will invalidate the obtained data if the appropriate experimental model is not chosen for the study. If the wrong experimental model is chosen, it will result in both economic and time loss. For these reasons, how and which model will be applied in internal and surgical branches in experimental studies and subject selection constitute an important problem. Choosing a suitable subject for the study increases the applicability of the studies and ensures that positive results can be obtained. In our article, we planned to compile the experimental models applied in the literature with different aspects including their advantages and disadvantages and to provide the practitioner with ease of choice.

Keywords: Animal use; laboratory animal; experimental animal models; proper animal selection
ÖZET
 Tıbbın ilerlemesinde ve günümüzdeki aşamaya gelmesinde, hayvan deneylerinin rolü önemli ölçüde etkilidir. Tıp ve veteriner alanlarındaki araştırmaların birçoğu deney hayvanı kullanımını gerektirmektedir. Bundan sonra yapılacak olan deneysel çalışmaların da hayvan deneylerinin katkılarıyla gerçekleşmesi olası bir gerçektir. Öte yandan, etik nedenlerden dolayı deneysel çalışmalarda insanlara yer verilememesi, hayvanların kullanımını zorunlu kılmaktadır. Deney hayvanlarının kullanıldığı çok sayıda model bulunmaktadır. Fakat deney hayvanlarının kullanımı, birtakım dezavantajları da beraberinde getirmektedir. Bilimsel olarak ya da herhangi başka bir amaç için deney hayvanları rastgele kullanılamazlar. Deney protokolü uygun yürütülmüş olsa da çalışma için uygun deney modeli seçilmez ise elde edilen verileri geçersiz kılacaktır. Yanlış deney modeli seçildiğinde, hem ekonomik hem de zaman kaybı ile sonuçlanacaktır. Bu nedenle deneysel çalışmalarda, dahili ve cerrahi branşlarda hangi modelin nasıl uygulanacağı ve denek seçimi önemli bir sorun oluşturmaktadır. Çalışmaya uygun denek seçimi, çalışmaların uygulanabilirliğini artırmakta ve olumlu sonuçlar alınabilmesini sağlamaktadır. Yazımızda, literatürde uygulanan deney modellerini avantaj ve dezavantajlarını da içeren farklı yönleriyle derlemeyi ve uygulayıcıya seçim kolaylığı sağlamayı planladık.

Anahtar Kelimeler: Hayvan kullanımı; laboratuvar hayvanı; deneysel hayvan modelleri; uygun hayvan seçimi
REFERENCES:
  1. Henry J, Baker J, Russell L. Research in laboratory animal and comparative medicine. In: James G, Fox Lynn C, Anderson Franklin M, Loew Fred W, eds. Laboratory Animal Medicine. 2nd ed. Amsterdam, Netherlands: Academic Press; 2002. p.1228-37.
  2. Hau J. Handbook of Labora­tory Animal Science Vol II Animal Models. Hau j, Van Hoosier L. ed. Induced (Experimental) Disease Models. 2nd ed. Boca Raton, US: CRC Press; 2003. p.1-9.[Crossref] [PMC] 
  3. Barbee RW, Turner PV. Incorporating laboratory animal science into responsible biomedical research. ILAR J. 2019;31;60(1):9-16.[Crossref] [PubMed] 
  4. de Aguilar-Nascimento JE. Fundamental steps in experimental design for animal studies. Acta Cir Bras. 2005;20(1):2-8.[Crossref] [PubMed] 
  5. Lipman NS, Perkins SE. Factors that may influence animal research. In: Fox J, Anderson L, Loew F, Quimby F, eds. Laboratory Animal Medicine. 2nd ed. Amsterdam, Netherlands: Academic Press; 2002; p.1143-65.[Crossref] 
  6. Wood MW, Hart LA. Selecting appropriate animal models and strains: making the best use of research, information and outreach. AATEX. 2008;14 Special Issue:303-6.[Link] 
  7. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;30;7(3):e1000245.[Crossref] [PubMed] [PMC] 
  8. Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 1953;107(3):385-93.[PubMed] 
  9. Koster R, Anderson M, De Beer EJ. Acetic acid for analgesic screening. Federation Proceedings. 1959;18(1):412-7.[Link] 
  10. Raj PP. Ağrı taksonomisi. Erdine S, editör. Ağrı. 1. Baskı. İstanbul: Alemdar Ofset; 2000. p.12-20.
  11. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol. 2001;19;429(1-3):1-11.[Crossref] [PubMed] 
  12. Wang LX, Wang ZJ. Animal and cellular models of chronic pain. Adv Drug Deliv Rev. 2003;28;55(8):949-65.[Crossref] [PubMed] 
  13. Wuarin-Bierman L, Zahnd GR, Kaufmann F, Burcklen L, Adler J. Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia. 1987;30(8):653-8.[PubMed] 
  14. Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol. 1995;133(1):64-72.[Crossref] [PubMed] 
  15. Authier N, Fialip J, Eschalier A, Coudoré F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett. 2000;15;291(2):73-6.[Crossref] [PubMed] 
  16. Vural A, Özatik rslan A, Uzunlar K. Deneysel spinal kord travmalarında dopamin ile kombine nimodipin ve nalorfinin etkileri. Ankara Patoloji Bülteni. 1994;11(2):21-5.[Link] 
  17. Döşoğlu M, Kırış T, İzgi N, Ünal ÖF. Omurilik travmalarında ikincil hasar mekanizmaları. Ulus Travma Acil Cerrahi Derg. 1998;4(3):147-57.[Link] 
  18. Montilla MP, Cabo J, Navarro MC, Risco S, Jimenez J, Aneiros J, et al. The protective and curative action of Withania frutescens leaf extract against CCl4-induced hepatotoxicity. Phytotherapy Research. 1990;4(6):212-5.[Crossref] 
  19. Chan-Yeung M. A clinician's approach to determine the diagnosis, prognosis, and therapy of occupational asthma. Med Clin North Am. 1990;74(3):811-22.[Crossref] [PubMed] 
  20. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161(5):1720-45.[Crossref] [PubMed] 
  21. Dietrich WF, Miller J, Steen R, Merchant MA, Damron-Boles D, Husain Z, et al. A comprehensive genetic map of the mouse genome. Nature. 1996;14;380(6570):149-52. Erratum in: Nature. 1996;9;381(6578):172.[Crossref] [PubMed] 
  22. Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z, et al. New insights into the pathogenesis of asthma. J Clin Invest. 2003;111(3):291-7.[Crossref] [PubMed] [PMC] 
  23. Boskabady MH, Rahbardar MG, Jafari Z. The effect of safranal on histamine (H(1)) receptors of guinea pig tracheal chains. Fitoterapia. 2011;82(2):162-7.[Crossref] [PubMed] 
  24. Zosky GR, von Garnier C, Stumbles PA, Holt PG, Sly PD, Turner DJ, et al. The pattern of methacholine responsiveness in mice is dependent on antigen challenge dose. Respir Res. 2004;23;5(1):15.[Crossref] [PubMed] [PMC] 
  25. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-94.[Crossref] 
  26. Howard RB, Chu H, Zeligman BE, Marcell T, Bunn PA, McLemore TL, et al. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res. 1991;15;51(12):3274-80.[PubMed] 
  27. Hastings RH, Burton DW, Quintana RA, Biederman E, Gujral A, Deftos LJ, et al. Parathyroid hormone-related protein regulates the growth of orthotopic human lung tumors in athymic mice. Cancer. 2001;15;92(6):1402-10.[Crossref] [PubMed] 
  28. Kellar A, Egan C, Morris D. Preclinical murine models for lung cancer: clinical trial applications. Biomed Res Int. 2015;2015:621324.[Crossref] [PubMed] [PMC] 
  29. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E, et al. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009;1;69(3):873-8.[Crossref] [PubMed] 
  30. Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res. 2007;1;13(5):1540-51.[Crossref] [PubMed] 
  31. Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, et al. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Invest. 2013;93(10):1137-46.[Crossref] [PubMed] 
  32. Akhtar S, Meeran SM, Katiyar N, Katiyar SK. Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting insulin-like growth factor binding protein-3, tumor cell proliferation, and angiogenic factors. Clin Cancer Res. 2009;1;15(3):821-31. Erratum in: Clin Cancer Res. 2018;1;24(23):6101.[Crossref] [PubMed] 
  33. Chen MF, Chen WC, Wu CT, Lin PY, Shau H, Liao SK, et al. p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment. Int J Radiat Oncol Biol Phys. 2006;1;66(5):1461-72.[Crossref] [PubMed] 
  34. Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res. 2004;1;10(5):1633-44.[Crossref] [PubMed] 
  35. McLemore TL, Liu MC, Blacker PC, Gregg M, Alley MC, Abbott BJ, et al. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res. 1987;1;47(19):5132-40.[PubMed] 
  36. Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol. 2007;59(2):183-95.[Crossref] [PubMed] 
  37. Feng Z, Zhao G, Yu L, Gough D, Howell SB. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol. 2010;65(5):923-30.[Crossref] [PubMed] [PMC] 
  38. Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res. 1997;88(12):1205-10.[Crossref] [PubMed] [PMC] 
  39. Sakai Y, Sasahira T, Ohmori H, Yoshida K, Kuniyasu H. Conjugated linoleic acid reduced metastasized LL2 tumors in mouse peritoneum. Virchows Arch. 2006;449(3):341-7.[Crossref] [PubMed] 
  40. Akbay E, Onur MA, Gürpınar ÖA. [Myocardial infarction models]. Turkiye Klinikleri J Cardiovasc Surg-Special Topics. 2013;5(3):49-57.[Link] 
  41. Karasu-Minareci E, Öğütman Ç. [Experimental animal models for cardiovascular diseases]. Turkiye Klinikleri J Cardiovasc Sci. 2011;23(1):65-74.[Link] 
  42. Bopda OS, Longo F, Bella TN, Edzah PM, Taïwe GS, Bilanda DC, et al. Antihypertensive activities of the aqueous extract of Kalanchoe pinnata (Crassulaceae) in high salt-loaded rats. J Ethnopharmacol. 2014;28;153(2):400-7.[Crossref] [PubMed] 
  43. Qui-ones M,Guerrero L, Suarez M, Pons Z, Aleixandre A, Arola L, et al. Low-molecular procyanidin rich grape seed extract exerts antihypertensive effect in males spontaneously hypertensive rats. Food Research International. 2013;51(2):587-95.[Crossref] 
  44. Sun ZJ, Zhang ZE. Historic perspectives and recent advances in major animal models of hypertension. Acta Pharmacol Sin. 2005;26(3):295-301.[Crossref] [PubMed] 
  45. Selye H. Production of nephrosclerosis by overdosage with desoxycorticosterone acetate. Can Med Assoc J. 1942;47(6):515-9.[PubMed] [PMC] 
  46. Terris JM, Berecek KH, Cohen EL, Stanley JC, Whitehouse WM Jr, Bohr DF, et al. Deoxycorticosterone hypertension in the pig. Clin Sci Mol Med Suppl. 1976;3:303s-5s.[Crossref] [PubMed] 
  47. Bois P, Selye H. The hormonal production of nephrosclerosis and periarteritis nodosa in the primate. Br Med J. 1957;26;1(5012):183-6.[Crossref] [PubMed] [PMC] 
  48. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in male and female rats. Hypertension. 1997;29(1 Pt 2):494-9.[Crossref] [PubMed] 
  49. Dahl LK, Heine M, Tassinari L. Effects of chronic excess salt ingestion. Further demonstration that genetic factors influence the development of hypertension: evidence from experimental hypertension due to cortisone and to adrenal regeneration. J Exp Med. 1965;1;122(3):533-45.[Crossref] [PubMed] [PMC] 
  50. Knowlton AI, Loeb EN, Stoerk HC, Whıte JP, Heffernan JF. Induction of arterial hypertension in normal and adrenalectomized rats given cortisone acetate. J Exp Med. 1952;96(3):187-205.[Crossref] [PubMed] [PMC] 
  51. Ergül Erkeç Ö. Tıbbi çalışmalarda hayvan modelleri. Int J Hum Sci Uluslararası İnsan Bilim Derg. 2014;50-63.[Crossref] 
  52. Baskurt OK, Marshall-Gradisnik S, Pyne M, Simmonds M, Brenu E, Christy R, et al. Assessment of the hemorheological profile of koala and echidna. Zoology (Jena). 2010;113(2):110-7.[Crossref] [PubMed] [PMC] 
  53. Bailey SR, Habershon-Butcher JL, Ransom KJ, Elliott J, Menzies-Gow NJ. Hypertension and insulin resistance in a mixed-breed population of ponies predisposed to laminitis. Am J Vet Res. 2008;69(1):122-9.[Crossref] [PubMed] 
  54. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.[Crossref] [PubMed] 
  55. Emanuela F, Grazia M, Marco de R, Maria Paola L, Giorgio F, Marco B, et al. Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab. 2012;2012:476380.[Crossref] [PubMed] [PMC] 
  56. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514-20.[Crossref] [PubMed] 
  57. Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. Diab Vasc Dis Res. 2004;1(2):68-75.[Crossref] [PubMed] 
  58. Caltabilota TJ, Earl LR, Thompson DL Jr, Clavier SE, Mitcham PB. Hyperleptinemia in mares and geldings: assessment of insulin sensitivity from glucose responses to insulin injection. J Anim Sci. 2010;88(9):2940-9.[Crossref] [PubMed] 
  59. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011;2011:351982.[Crossref] [PubMed] [PMC] 
  60. Polotsky VY. Mouse model of the metabolic syndrome: the quest continues. J Appl Physiol (1985). 2007;102(6):2088-9.[Crossref] [PubMed] 
  61. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003;284(6):F1138-44.[Crossref] [PubMed] 
  62. Shafrir E, Ziv E. A useful list of spontaneously arising animal models of obesity and diabetes. Am J Physiol Endocrinol Metab. 2009;296(6):E1450-2.[Crossref] [PubMed] 
  63. Silva APS, Guimarâes DED, Mizurini DM, Maia IC, Ortiz-Costa S, Sardinha FL, et al. Dietary fatty acids early in life affect lipid metabolism and adiposity in young rats. Lipids. 2006;41(6):535-41.[Crossref] [PubMed] 
  64. Akagiri S, Naito Y, Yoshikawa T. Diyet and metabolic syndrome. J Biol Macromol. 2009;9(2):39-48.[Link] 
  65. Basciano H, Federico L, Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond). 2005;21;2(1):5.[Crossref] [PubMed] [PMC] 
  66. Santos MP, França SA, Santos JT, Buzelle SL, Bertolini GL, Garófalo MA, et al. A low-protein, high-carbohydrate diet increases fatty acid uptake and reduces norepinephrine-induced lipolysis in rat retroperitoneal white adipose tissue. Lipids. 2012;47(3):279-89.[Crossref] [PubMed] 
  67. Desrois M, Sidell RJ, Gauguier D, King LM, Radda GK, Clarke K, et al. Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart. Cardiovasc Res. 2004;1;61(2):288-96.[Crossref] [PubMed] 
  68. Mizoguchi A, Mizoguchi E. Animal models of IBD: linkage to human disease. Curr Opin Pharmacol. 2010;10(5):578-87.[Crossref] [PubMed] [PMC] 
  69. DeVoss J, Diehl L. Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease. Toxicol Pathol. 2014;42(1):99-110.[Crossref] [PubMed] 
  70. Jones-Hall YL, Grisham MB. Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease. Pathophysiology. 2014;21(4):267-88.[Crossref] [PubMed] 
  71. te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW, et al. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(3):325-30.[Crossref] [PubMed] 
  72. Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;15;7(8):4557-76.[PubMed] [PMC] 
  73. Gibson-Corley KN, Olivier AK, Meyerholz DK. Principles for valid histopathologic scoring in research. Vet Pathol. 2013;50(6):1007-15.[Crossref] [PubMed] [PMC] 
  74. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347-69.[Crossref] [PubMed] 
  75. Bouma G, Kaushiva A, Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology. 2002;123(2):554-65.[Crossref] [PubMed] 
  76. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009;15(3):341-52.[Crossref] [PubMed] [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com